These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37006273)

  • 1. Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt's lymphoma with TP53 mutations.
    Zhang Q; Zhu X; Liu B; Zhang Y; Xiao Y
    Front Immunol; 2023; 14():1127868. PubMed ID: 37006273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR19/22 T cell therapy in adult refractory Burkitt's lymphoma.
    Zhou X; Ge T; Li T; Huang L; Cao Y; Xiao Y; Zhen M; Chen L; Zhou J
    Cancer Immunol Immunother; 2021 Aug; 70(8):2379-2384. PubMed ID: 33459843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case Report: Unedited allogeneic chimeric antigen receptor T cell bridging to conditioning-free hematopoietic stem cell transplantation for a child with refractory Burkitt lymphoma.
    Yang X; Luo C; Qian J; Huang X; Zhang J; Wang J; Luo C; Qin X; Li B; Chen J
    Front Immunol; 2023; 14():1219872. PubMed ID: 37736096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT.
    Wei J; Xiao M; Mao Z; Wang N; Cao Y; Xiao Y; Meng F; Sun W; Wang Y; Yang X; Chen L; Zhang Y; Zhu H; Zhang S; Zhang T; Zhou J; Huang L
    Signal Transduct Target Ther; 2022 Apr; 7(1):101. PubMed ID: 35399106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.
    Du J; Zhang Y
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1575-1582. PubMed ID: 32222815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
    Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
    Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.
    Wu J; Cao Y; Zhang Q; Liu W; Zhou X; Ming X; Meng F; Zhang Y; Li C; Huang L; Wei J; Zheng M; Zhang S; Zhang T; Zhu X; Wang N; Wang J; Wang G; Zhou J; Liu B; Xiao Y
    Front Immunol; 2022; 13():879983. PubMed ID: 35669773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful Treatment of Pediatric Refractory Burkitt Lymphoma PTLD after Liver Transplantation using Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
    Wang T; Feng M; Luo C; Wan X; Pan C; Tang J; Xue F; Yin M; Lu D; Xia Q; Li B; Chen J
    Cell Transplant; 2021; 30():963689721996649. PubMed ID: 33631963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
    Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome.
    Chen L; Xu B; Long X; Gu J; Lou Y; Wang D; Cao Y; Wang N; Li C; Wang G; Wang Y; Zhu L; Wang J; An H; Xiao M; Xiao Y; Zhou J
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32345625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation.
    Yan N; Wang N; Wang G; Huang L; Li C; Wang D; Wang J; Huang L; Meng F; Wei J; Chen L; Mao X; Zhou J; Zhang Y; Cao Y
    Cytotherapy; 2022 Aug; 24(8):841-849. PubMed ID: 35256277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt's Lymphoma.
    Kenkel TJ; Sridhar N; Hammons LR; Hintzke M; Shah NN
    Med Sci (Basel); 2023 Oct; 11(4):. PubMed ID: 37873752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of
    Shouval R; Alarcon Tomas A; Fein JA; Flynn JR; Markovits E; Mayer S; Olaide Afuye A; Alperovich A; Anagnostou T; Besser MJ; Batlevi CL; Dahi PB; Devlin SM; Fingrut WB; Giralt SA; Lin RJ; Markel G; Salles G; Sauter CS; Scordo M; Shah GL; Shah N; Scherz-Shouval R; van den Brink M; Perales MA; Palomba ML
    J Clin Oncol; 2022 Feb; 40(4):369-381. PubMed ID: 34860572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
    An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
    BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy.
    Yang TT; Meng Y; Kong DL; Wei GQ; Zhang MM; Wu WJ; Shi JM; Luo Y; Zhao YM; Yu J; Jing RR; Zhao MY; Zhao HL; Huang H; Hu YX
    Front Immunol; 2022; 13():934442. PubMed ID: 36110859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-examining the role of hematopoietic stem cell transplantation in relapsed large B-cell lymphoma in the era of chimeric antigen receptor (CAR) T-cell therapy.
    Moyo TK; Vaidya R
    Front Oncol; 2024; 14():1397186. PubMed ID: 39211553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and prognosis of rrDLBCL with TP53 mutations and a high-risk subgroup represented by the co-mutations of DDX3X-TP53.
    Gao F; Hu K; Zheng P; Shi H; Ke X
    Cancer Med; 2023 May; 12(9):10267-10279. PubMed ID: 36971051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.
    Bliven SP; Shea L; Bal S; Goyal G; Mehta A; Narkhede M
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):825-834. PubMed ID: 35869021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
    Beitinjaneh A; Kaufman A; Wang Y; Jain P; Srour SA; Wang M
    Curr Treat Options Oncol; 2022 Nov; 23(11):1614-1625. PubMed ID: 36227407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
    Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
    Front Immunol; 2021; 12():755549. PubMed ID: 34777367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.